Daré Bioscience rises as Bayer exits Ovaprene partnership deal

Dare Bioscience

01/12/2025 13:28

** Shares of women's health firm Daré Bioscience DARE.O rise 6% to $1.91 premarket

** Co says it will regain full rights to its experimental contraceptive ovaprene after Bayer HealthCare decided to end its partnership with the U.S. biotech firm

** The move gives Daré control over ovaprene as it enters late-stage testing, offering more flexibility on commercialization - co

** Daré CEO Sabrina Martucci Johnson says recent trial results showed ovaprene was safe and well tolerated, with pregnancy rates matching expectations

** Co expects to finish enrolling patients in its ongoing late-stage trial next year; study funded by grants including Gates Foundation

** Including session's move, stock down ~41% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))